Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MWN-AI** Summary
Femasys Inc. (NASDAQ: FEMY), a prominent biomedical firm dedicated to enhancing fertility treatment and non-surgical permanent birth control options for women, announced the granting of stock options to two new non-executive employees. These options, totaling 185,000 shares, were issued at exercise prices of $0.50 and $0.57, reflecting Femasys' common stock closing rates on their employment start date in February 2026. The grants were approved by the company’s Compensation Committee as part of their employment inducements under Nasdaq Listing Rule 5635(c)(4).
The stock options will be vested gradually, with 25% vesting on the first anniversary of employment and the remaining shares vesting at a rate of 25% per year over the following three years, contingent on continued employment.
Femasys is committed to expanding access to innovative fertility and birth control solutions through its diverse range of patent-protected products. Their portfolio includes FemaSeed® Intratubal Insemination (ITI), which has shown to significantly improve pregnancy rates compared to traditional methods, and FemBloc®, the first non-surgical, in-office permanent contraception method approved in various countries. FemBloc, which received full regulatory approval in Europe and New Zealand in 2025, is anticipated to make a significant impact on the market through strategic partnerships. Additionally, FemChec® offers an ultrasound-based diagnostic to confirm procedure success.
Femasys continues its focus on regulatory approvals, with ongoing clinical trials for its products, including enrollment efforts for the FemBloc candidate. The company emphasizes the potential market impact of its innovative solutions while navigating the inherent risks of the biomedical industry.
MWN-AI** Analysis
Femasys Inc. (NASDAQ: FEMY) recently announced a strategic move by awarding stock options to new employees as part of its growth strategy within the growing field of women’s reproductive health. The options, granted at exercise prices considerably lower than the market price, reflect a commitment to attract talent and signal positive internal momentum.
From an investment standpoint, Femasys presents an intriguing opportunity. The company operates in a niche but increasingly important sector with its innovative solutions like FemaSeed and FemBloc, which have shown promising clinical results and are gearing towards broader commercial availability. The successful commercialization of FemBloc in key international markets post-regulatory approvals could significantly boost revenues and validate the company’s market position.
However, investors should remain cautious. The reported inducement grants, while indicative of growth, also imply substantial expectations from the new hires, particularly around the impending FDA trials for FemBloc. These trials carry inherent risks, and any delays or unforeseen results could adversely affect share prices. Additionally, while Femasys aims for profitability through strategic partnerships for product rollout, the company's ability to execute on these partnerships is crucial.
Monitoring the progression of the FINALE pivotal trial and broader adoption rates of Femasys' offerings will be essential for assessing future performance. If successful, Femasys could capture significant market share in a rapidly evolving landscape, appealing to investors focused on health innovation.
In conclusion, while Femasys (FEMY) shows potential for capital appreciation driven by innovation and strategic hiring, urgent attention to regulatory milestones and execution of growth strategies will be critical in these early stages. Investors are encouraged to conduct thorough due diligence and consider the inherent risks before fully committing to positions in FEMY.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
ATLANTA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today it has granted to two new non-executive employees who began their employment with Femasys in February 2026 options to purchase 185,000 shares of Femasys common stock.
These inducement grants were granted at an exercise price per share of $0.50 and $0.57, equal to the closing price of Femasys common stock on the date of employment as reported by Nasdaq. This grant was approved by the Compensation Committee of Femasys’ Board of Directors and made as an inducement material to employment to individuals hired by Femasys. The stock options will vest as to 25% of the shares underlying the stock option on the first anniversary of the commencement of employment, with the remaining shares vesting 25% each year over the following three years, subject to continued employment with Femasys. Femasys provides this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Femasys
Femasys is a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide through its broad, patent-protected portfolio of novel, in-office therapeutic and diagnostic products. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its lead product innovations in the U.S. and key international markets. Femasys’ fertility portfolio includes FemaSeed® Intratubal Insemination (ITI), a groundbreaking first-step infertility treatment; FemSperm®, a CLIA waived sperm preparation and analysis product line; and FemVue®, a companion diagnostic for fallopian tube assessment. Published clinical trial data demonstrate that FemaSeed achieved more than double the pregnancy rates of traditional IUI, with a comparable safety profile and high patient and practitioner satisfaction.1
FemBloc® permanent birth control is the first and only non-surgical, in-office alternative to centuries-old surgical sterilization that received full regulatory approval in Europe in June 2025, the UK in August 2025, and New Zealand in September 2025. Commercialization of this highly cost-effective, convenient and significantly safer approach will be completed through strategic partnerships in select European countries. Alongside FemBloc, the FemChec®, diagnostic product provides an ultrasound-based test to confirm procedural success. Published data from initial clinical trials demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.2 For U.S. FDA approval, enrollment in the FINALE pivotal trial (NCT05977751) is on-going.
Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.
References
1Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08.
2Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. doi: 10.33140/JGRM.09.01.05.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
David Gutierrez, Dresner Corporate Services, (312) 780-7204, dgutierrez@dresnerco.com
Nathan Abler, Dresner Corporate Services, (714) 742-4180, nabler@dresnerco.com
FAQ**
What are the strategic implications of the stock options granted to new employees at Femasys Inc. (NASDAQ: FEMY) in terms of recruitment and retention of talent in the competitive biomedical sector?
How does Femasys Inc. (FEMY) plan to commercialize its products, such as FemBloc and FemaSeed, following their recent regulatory approvals and clinical trial advancements?
Given the collaborative approach outlined by Femasys Inc. (FEMY) for market entry, which strategic partnerships are being considered to enhance the commercialization of FemBloc in European markets?
What are the primary risks and uncertainties that Femasys Inc. (NASDAQ: FEMY) anticipates in securing FDA approval for its FemBloc product candidate, and how are these being managed?
**MWN-AI FAQ is based on asking OpenAI questions about Femasys Inc. (NASDAQ: FEMY).
NASDAQ: FEMY
FEMY Trading
4.22% G/L:
$0.5711 Last:
100,414 Volume:
$0.5567 Open:
